Full Press Release Details
NATICK, Mass., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced the presentation of several studies at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.
"We are excited to present data from multiple studies at ASH and to discuss Selinexor," commented Sharon Shacham, Ph.D., founder, Chief Scientific Officer and President of Research and Development of Karyopharm.
Presentations include:
Preliminary Evidence of Anti Tumor Activity of Selinexor (KPT-330) in a Phase I Trial of a First-In-Class Oral Selective Inhibitor of Nuclear Export (SINE) in Patients with Relapsed /Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
John Kuruvilla, M.D., Princess Margaret Cancer Centre, University of Toronto, Toronto, ON.
Sunday, December 8, 6:15 PM-6:30 PM, La Nouvelle Ballroom AB
Oral Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Novel Agents in Lymphoma Therapy
Effects of Inhibition of XPO1/CRM1-Dependent Nuclear Export by Selinexor (KPT-330), Alone and in Combination with Carfilzomib (CFZ), on Apoptosis and Autophagy in Multiple Myeloma (MM)
Shaun Rosebeck, Ph.D., University of Chicago Medicine, Chicago, IL.
Monday, December 9, 7:30 AM-7:45 AM, Room 391-392
Oral Session: 652. Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Drug Resistance
Inhibition of Nuclear Transport Modulator CRM1 for the Treatment of Acute Myeloid Leukemia (AML)
Michael Rettig, Ph.D., Washington University School of Medicine, St. Louis, MO.
Monday, December 9, 7:30 AM-7:45 AM, La Nouvelle Ballroom C
Oral Session: 615. Acute Myeloid Leukemia - Therapy excluding Transplantation: Translational Studies
Molecular Mechanisms of Inhibition of Ribosomal Biogenesis and Translational Flux by the Selective Inhibitor of Nuclear Export (SINE) XPO1/CRM1 Antagonist KPT-185 in Mantle Cell Lymphoma
Yoko Tabe, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Tuesday, December 10, 8:15 AM-8:30 AM, Room 275-277
Oral Session: 604. Molecular Pharmacology, Drug Resistance: Targeting PI3K/AKT/mTOR, Nuclear Export, and Resistance Mechanisms
Anti Tumor Activity of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor of Nuclear Export (SINE) XPO1/CRM1 Antagonist in Patients with Relapsed/Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)
Christine Chen, M.D., Princess Margaret Cancer Centre, University of Toronto, Toronto, ON.
Saturday, December 7, 5:30 PM-7:30 PM, Hall G
Poster Session: 653. Myeloma - Therapy, excluding Transplantation: Poster I
Decitabine Priming Enhances the Antileukemic Effects of the Selective Inhibitor of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) in Acute Myeloid Leukemia (AML)
Parvathi Ranganathan, Ph.D., Ohio State University Comprehensive Cancer Center, Columbus, OH.
Saturday, December 7, 5:30 PM-7:30 PM, Hall E
Poster Session: 615. Acute Myeloid Leukemia - Therapy excluding Transplantation: Poster I
Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor of Nuclear Export (SINE) in Patients with Advanced Acute Myelogenous Leukemia (AML)
Michael Savona, M.D., Sarah Cannon Cancer Center, Nashville, TN.
Saturday, December 7, 5:30 PM-7:30 PM, Hall E
Poster Session: 615. Acute Myeloid Leukemia - Therapy excluding Transplantation: Poster I
CRM1 as a New Therapeutic Target for Non-Hodgkin Lymphoma
Yuankai Shi, M.D., Ph.D., Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing China
Saturday, December 7, 5:30 PM-7:30 PM, Hall E
Poster Session: 604. Molecular Pharmacology, Drug Resistance: Poster I
XPO1 Inhibition Disrupts Ribosomal Subunits Assembly and Induces Multiple Myeloma (MM) Cell Death
Ines Tagoug, Ph.D., University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB.
Sunday, December 8, 6:30 PM-8:30 PM, Hall G
Poster Session: 652. Myeloma - Pathophysiology and Pre-Clinical Studies excluding Therapy: Poster II
An Unbiased shRNA Library Screen Identifies Nucleocytoplasmic Transport as a Potential Target for Treatment of Chronic Myeloid Leukemia
Jamshid Khorashad, M.D. Ph.D., University of Utah, Huntsman Cancer Institute, Salt Lake City, UT.
Sunday, December 8, 6:30 PM -8:30 PM, Hall E
Poster Session: 631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster II
Novel Inhibitors of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML "primagrafts," Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells
Julia Etchin, Ph.D., Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Monday, December 9, 6:00 PM-8:00 PM, Hall E
Poster Session: 615. Acute Myeloid Leukemia - Therapy excluding Transplantation: Poster III
Induction of p53 Transcription and Apoptosis by XPO1 Inhibition in Mantle Cell Lymphoma
Kensuke Kojima, M.D., Ph.D., Saga University, Saga, Japan; University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Monday, December 9, 6:00 PM-8:00 PM, Hall E
Poster Session: 604. Molecular Pharmacology, Drug Resistance: Poster II
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell, thereby leading to their accumulation in the nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Karyopharm constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements about the timing and type of data to be presented at the American Society of Hematology 2013 Annual Meeting, Karyopharm's ability to execute on its strategic plans, and the therapeutic potential of Selinexor. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the unproven nature of our discovery and development approach and uncertainties inherent in preclinical testing and clinical trials, among other factors discussed in the "Risk Factors" section of the prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.